Improvement in
attention-deficit/hyperactivity disorder (
ADHD) symptoms vs. placebo was reported in a series of pediatric clinical trials of
viloxazine extended-release capsules (
viloxazine ER; Qelbree™). This post hoc analysis of those studies evaluated the effect of
viloxazine ER on learning and school problems (LSPs). We used data from four Phase 3 placebo-controlled trials of 100-600 mg/day
viloxazine ER (N = 1354; 6-17 years of age). LSPs were evaluated using the School domain of the Weiss Functional Impairment Rating Scale-Parent Report (WFIRS-P-S) and the Learning Problems content scale of the Conners 3rd Edition-Parent Short Form (C3PS-LP) at baseline and end of study (≥ Week 6).
ADHD symptoms were assessed weekly using the
ADHD Rating Scale 5th Edition. The analyses were performed using the general linear mixed model with participant as a random effect. The responder analyses were performed using the Chi-square test.
Viloxazine ER demonstrated significantly greater improvements in WFIRS-P-S (p < 0.0001) and C3PS-LP (p = 0.0113) scores vs. placebo. The response rate for the WFIRS-P-S was significantly greater for
viloxazine ER vs. placebo (p = 0.001), and the number needed to treat (NNT) was 10.3 (effect size 0.7). Conversely, response rates for C3PS-LP did not differ between groups (p = 0.9069). In addition to
ADHD symptoms improvement demonstrated in previous studies,
viloxazine ER significantly reduced LSPs in pediatric subjects with
ADHD. The responder analyses and NNT estimates indicate that a substantial number of children and adolescents with
ADHD treated with
viloxazine ER improved in clinically assessed LSPs.